Accelerate Diagnostics AXDX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Accelerate Diagnostics (AXDX)
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.12Market Cap
$28.05 MillionPrice-Earnings Ratio
-0.43Total Outstanding Shares
25.04 Million SharesTotal Employees
134Dividend
No dividendIPO Date
November 19, 1996SIC Description
Laboratory Analytical InstrumentsPrimary Exchange
NASDAQType
Common StockHeadquarters
3950 s. country club road #470, Tucson, AZ, 85714Homepage
https://www.acceleratediagnostics.com
Historical Stock Splits
If you bought 10 shares of AXDX before July 12, 2023, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| July 12, 2023 | 1-for-10 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $27.75 Million |
| Net Cash Flow From Investing Activities | $-619,000 |
| Net Cash Flow From Investing Activities, Continuing | $-619,000 |
| Exchange Gains/Losses | $-717,000 |
| Net Cash Flow From Operating Activities | $-26.88 Million |
| Net Cash Flow, Continuing | $246,000 |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Cost Of Revenue | $9.02 Million |
| Net Income/Loss Attributable To Parent | $-53.45 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Revenues | $11.91 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-53.45 Million |
| Basic Earnings Per Share | $-2.59 |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-54.15 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-54.15 Million |
| Comprehensive Income/Loss Attributable To Parent | $-54.15 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Assets | $1.00 Million |
| Fixed Assets | $2.88 Million |
| Accounts Payable | $4.71 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $4.88 Million |
| Other Current Liabilities | $12.53 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about AXDX from trusted financial sources
ⓒ 2025 Financhle. All Rights Reserved.